Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091650 · ClinicalTrials.gov registry record · Phase 3
Olanzapine in Patients With Borderline Personality Disorder
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00091650 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 300 participants.
The verdict
NCT00091650, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The goals of this study are to determine: the safety of olanzapine and any side effects that might be associated with it, how olanzapine compares to placebo, whether olanzapine can help patients with symptoms of Borderline Personality Disorder (BPD), and how much olanzapine should be given to patients.
Interventions
- DRUG placebo
- DRUG Olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091650
The ClinicalTrials.gov registry entry for NCT00091650 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00091650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091650 about?
NCT00091650 is a clinical study titled "Olanzapine in Patients With Borderline Personality Disorder". The goals of this study are to determine: the safety of olanzapine and any side effects that might be associated with it, how olanzapine compares to placebo, whether olanzapine can help patients with symptoms of Borderline Personality Disorder (BPD), and how much olanzapine should be given to patien...
What is the current status of trial NCT00091650?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00091650?
The interventions under investigation include: placebo (DRUG), Olanzapine (DRUG).
Who is sponsoring clinical trial NCT00091650?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.